218 related articles for article (PubMed ID: 15738379)
1. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Rosiñol L; Montoto S; Cibeira MT; Bladé J
Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
3. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
5. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Hsiao SC; Wang MC; Chang H; Pei SN
Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced rhabdomyolysis in multiple myeloma.
Cibeira MT; Mercadal S; Arenillas L; Muntañola A; Salamero O; Bladé J
Acta Haematol; 2006; 116(3):203-6. PubMed ID: 17016040
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Cornelis T; Beckers EA; Driessen AL; van der Sande FM; Koek GH
Clin Toxicol (Phila); 2012 Jun; 50(5):444-5. PubMed ID: 22462599
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
11. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
[No Abstract] [Full Text] [Related]
12. [Aggravated post-herpetic neuralgia due to bortezomib].
Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
[TBL] [Abstract][Full Text] [Related]
13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
14. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced histiocytoid Sweet syndrome.
Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
17. Images in clinical Medicine. Bortezomib-induced skin lesions.
Agterof MJ; Biesma DH
N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
[No Abstract] [Full Text] [Related]
18. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
[TBL] [Abstract][Full Text] [Related]
19. Management of treatment-related adverse events in patients with multiple myeloma.
Mateos MV
Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
[TBL] [Abstract][Full Text] [Related]
20. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
[Next] [New Search]